Skip to main content

Molecular Devices Pays $11M Cash for Xsira s Transfluor Imaging Technology

NEW YORK, March 10 (GenomeWeb News) - Molecular Devices has acquired Xsira Pharmaceutical's Transfluor Imaging technology assets, the Sunnyvale, Calif.-based biotech tools company said late yesterday. 


Molecular Devices paid $11 million in cash for the technology, which is used for visualizing cellular events and detecting receptor activation. The firm said that the acquisition will strengthen its effort to provide imaging solutions to the drug-discovery market. It plans to begin licensing the technology to customers in the second quarter of 2005.


Xsira Pharmaceuticals, which developed the technology with Duke University, said it will now focus on drug discovery, and said that Molecular Devices will license its Transfluor technology back to its original owner to aid in that effort.


Molecular Devices is in the financial position to make such a purchase. It reported a 43-percent increase in fourth quarter revenues for 2004 in February.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.